Johnson & Johnson beats Wall Street expectations on profit, misses on revenue

Earnings

Johnson & Johnson headquarters in New Brunswick, N.J.

Mel Evans | AP

Johnson & Johnson‘s fiscal fourth-quarter profit beat Wall Street’s expectations but missed slightly on revenue, the company said Wednesday.

Here’s what the company reported compared with Wall Street estimates, based on a survey of analysts by Refinitiv:

  • Adjusted earnings per share: $1.88 versus $1.87 expected
  • Revenue: $20.74 billion versus $20.8 billion expected

J&J’s stock was essentially flat in pre-market trading after the announcement.

“We delivered strong underlying sales and earnings growth in 2019, driven by the strength of our Pharmaceutical business, accelerating performance in our Medical Devices business and improved profitability in our Consumer business,” J&J Chairman and CEO Alex Gorsky said in a release.

The company sees 2020 earnings of between $8.95 per share and $9.10 a share.

J&J, the maker of popular consumer product brands like Tylenol and Aveeno, is facing numerous lawsuits ranging from claims that its talc-based baby powder causes cancer to allegations that it helped fuel that nationwide opioid epidemic.

This is a developing story. Please check back for updates.

Products You May Like

Articles You May Like

Ask Larry: In What Month Does Social Security Consider Me To Be 62?
Inflation and recession fears are squeezing some industries more than others
What you need to know about staked ether, the token at the center of crypto’s liquidity crisis
‘The system is rusty’: Qantas CEO defends industry as airlines cancel thousands of flights
Make $228 An Hour In Your Spare Time